Latest International Markets News

Sea Forest Limited has reported a remarkable 236% increase in SeaFeed revenue for the first half of 2026, surpassing breakeven cattle commitments and securing new international partnerships.

MyEco Group has reported a 38% improvement in profit before tax and a 51% rise in normalised EBITDA for the first half of FY26, driven by operational restructuring and targeted sales growth. The company’s refreshed leadership team and strategic priorities set the stage for further expansion in sustainable packaging markets.

Advanced Braking Technology Ltd reported a robust 27.2% revenue increase and a 61.6% rise in net profit for H1 2026, driven by strong international sales and progress in autonomous braking technology.

NextEd Group Limited reported a 16.7% rise in underlying EBITDA and a 92% reduction in NPAT loss for H1 FY26, underpinned by AI integration and a strategic shift to higher-margin education segments.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

LaserBond Ltd has reported a robust first half of FY26, with revenue up 13.4% and net profit after tax more than doubling, underpinned by a significant licensing agreement with Komatsu and ongoing R&D investments.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.

Beamtree Holdings Limited reported a 2% rise in total revenue and a reduced net loss in the first half of FY26, driven by a 10% increase in recurring revenue. The company is advancing AI-powered healthcare products and has initiated a strategic review to unlock shareholder value.

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Marimaca Copper Corp. has launched a significant C$409 million global offering, combining treasury and secondary share sales, to fund key development and exploration activities at its flagship Chilean copper project.